�Kidney Research UK is to launch a pilot programme of national showing days for chronic kidney disease (CKD).� The screenings will take place from September until the end of November in four-spot centres across the UK.�
The national pilot is being conducted in association with the Queen Elizabeth Hospital Birmingham and aims to cover up to 2,000 people at four sites (namely London, Birmingham, Oldham, plus unitary other) each session targeting one of the risky groups, which include:
-�������� Black Africans and Caribbeans
-�������� South Asians
-�������� Those with a family history of kidney disease
-�������� People with diabetes
-�������� People with hypertension
The screening pilot, which is being sponsored by pharmaceutical companies Amgen and Roche, and supported by equipment from Siemens, is organism launched because CKD affects more than three billion people in the UK, many of whom ar unaware of the experimental condition.� If the programme proves successful, it could provide a model for national risk assessment.
Dr. Donal O'Donoghue, National Clinical Director for kidney tending comments:� "CKD is common, harmful and treatable. However it often goes undetected as sufferers oft display no symptoms, although people with high rip pressure (high blood pressure), diabetes and certain ethnical groups get a higher risk. Early detection however can have a significant impact on patient outcomes because changes in modus vivendi and diet can slow down the progression of the disease, delaying the progression to dialysis or transplantation."
Dr. Dwomoa Adu, the gaffer investigator for the cover pilot from Queen Elizabeth Hospital Birmingham, comments: "We now make drugs that reduce the rate at which renal disease progresses.� If we can identify people with� early stages of kidney disease, we tin can manage the condition and delay the need for dialysis and transplantation.� The way to do this is through the targeted screening of bad groups.� That way we can identify citizenry with CKD, before they reach a critical stage and help them to manage the condition with medication and lifestyle changes.� This is the right thing to do for both the patient and the NHS."
People wishing to find out if they are eligible to participate in the pilot can call the Kidney Health Information Line on 0845 300 1499 who will be able to notify them of screenings in their domain.
The appointments will terminal for some 45 transactions and patients will get their height, weight and blood press checked, and will be asked for blood and urine samples.�
Individuals who think they may be at risk should contact their doctor or alternatively contact the Kidney Health Information Line on 0845 300 1499 or visit hTTP://www.kidneyresearchuk.org.
About CKD
CKD, which affects over 3 million people in the UK, is difficult to detect early, as sufferers often display no symptoms, although people with high blood pressing (hypertension), diabetes and sure ethnic groups have a higher risk. Early detecting however can buoy have a significant shock on patient role outcomes because blood pressure treatment and changes in lifestyle derriere slow down the progress of the disease therefore delaying the need for dialysis or transplantation.
About Kidney Research UK
Kidney Research UK was formerly known as The National Kidney Research Fund, having changed its identify in October 2005. For over 40 years, it has been the UK's leading kidney charity, financial support research into the prevention, treatment, and management of kidney diseases. It likewise dedicates its work to patient guardianship and educational initiatives. http://www.kidneyresearchuk.org
About Queen Elizabeth Hospital
Queen Elizabeth Hospital is run by University Hospital Birmingham NHS Foundation Trust (UHB). UHB is the West Midlands' best performing Trust and in the top 20 in the nation (Healthcare Commission Annual Healthcheck, 2006). Queen Elizabeth and its sister hospital Selly Oak provide adult services for the population of South Birmingham and a range of specialist treatments for the wider region and beyond. It is a regional centre for burns, plastics, trauma and cancer. It is the largest solid organ transfer centre in Europe and has some of the shortest waiting times in the area. The Trust is currently building a new �545 million Super Hospital - the first base in Birmingham in 70 years. hTTP://www.uhb.nhs.uk
About Amgen
Amgen discovers, develops, manufacturers and delivers groundbreaking human therapeutics. A biotech pioneer since 1980, Amgen was unitary of the first companies to realize the fresh science's promise by delivery safe and effective medicines from science laboratory, to manufacture plant, to patient. Amgen therapeutics have changed the practice of medicine, portion millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential fresh medicines, Amgen remains committed to forward science to dramatically ameliorate people's lives. To ascertain more around Amgen's pioneering science and our critical medicines, visit http://www.amgen.com.
About Roche in the UK
Roche aims to improve people's health and quality of life with innovative products and services for the early sensing, prevention, diagnosis and treatment of disease. Part of one of the world's leading healthcare groups, Roche in the UK employs nearly 2,000 citizenry in pharmaceuticals and diagnostics. Globally Roche is the leader in diagnostics, and a major supplier of medicines for the treatment of cancer, transplantation, virology, bone and rheumatology, obesity and nephritic anaemia. Find out more at http://www.rocheuk.com
Roche in the UK
More info
